[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345330-105":59,"doc-detail-345330-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","five-dominant-amino-acid-substitution-signatures-shape-tumour-immunity","Five dominant amino acid substitution signatures shape tumour immunity","","Cancer mutational processes are numerous yet their immune-relevant functions remain unclear. The study tests the hypothesis that specific mutation sources preferentially generate amino acid substitutions that evade immune recognition, yielding immune-cold tumours independent of tissue type or mutational burden. By analyzing 9300 cancer exomes and conducting mutagenesis experiments, it maps links between mutagens, DNA repair defects, and amino acid substitution signatures (AAS). Five recurrent AAS emerge, including AAS4 associated with poor immunogenicity and immune-desert microenvironments, while HLA-B*07:02 selects immune-hot responses in this subgroup.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/five-dominant-amino-acid-substitution-signatures-shape-tumour-immunity/345330/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/five-dominant-amino-acid-substitution-signatures-shape-tumour-immunity/345330.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What core hypothesis does the study evaluate about mutations and immune response?","Question",{"text":112,"@type":113},"Certain mutation sources preferentially create amino acid substitutions that evade immune recognition, producing immune-cold tumours regardless of tissue or mutation load.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were amino acid substitution signatures identified in the work?",{"text":117,"@type":113},"The study combined analysis of 9300 cancer exomes with mutagenesis experiments to relate mutagens and DNA repair defects to amino acid substitution signatures.",{"name":119,"@type":110,"acceptedAnswer":120},"What is distinctive about AAS4 and its impact on antitumour immunity?",{"text":121,"@type":113},"AAS4, linked to alkylating agents and mismatch repair deficiency and enriched in kidney and liver cancers, is associated with poorly immunogenic neoepitopes and immune-desert microenvironments, leading to poor immunotherapy response.",{"name":123,"@type":110,"acceptedAnswer":124},"Why can some mismatch-repair–deficient cancers still show immune activity?",{"text":125,"@type":113},"In the AAS4 subgroup, certain HLA class I variants such as HLA-B*07:02 correlate with immune-hot tumours, where proline-enriched neopeptides stimulate T-cell proliferation in vitro.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},345330,1790665250,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nFive dominant amino acid substitution signatures shape tumour immunity  \nSzilvia Juhász 1,2,8 ✉, Benjamin Tamás Papp 1,3,4,8, Anna Tácia Fülöp 1,3,5,6, Zoltán Farkas 1,  \nDávid Kókai1,3, Dóra Alexandra Gyémánt1,3,5, Franciska Tóth 1,3,6, Zsóﬁa Nacsa1, Dóra Spekhardt 1  \n,  \nBalázs Koncz1,3, Péter Burkovics7, Csaba Pál 1 ✉ & Máté Manczinger 1,3,4 ✉  \nAbstract  \nAlthough numerous mutational processes operate in cancer, their functional impacts are unclear. We hypothesised that certain mutation sources preferentially generate amino acid substitutions that evade immune recognition, producing immune-cold tumours regardless of tissue or mutation load. By analysing 9300 cancer exomes and performing mutagenesis experiments, we mapped links between mutagens, DNArepair defects, and amino acid substitution signatures (AAS). Surprisingly, the spectrum collapsed into ﬁve recurrent AAS with distinct functional proﬁles. AAS4—generated by alkylating agents and mismatchrepair (MMR) deﬁciency and enriched in kidney and liver cancers—is less likely to accumulate hydrophobic residues, yielding poorly immunogenic neopeptides. These tumours display immune-desert microenvironmentsand respond poorly to immunotherapy. However, certain human leukocyte antigen (HLA) class I variants, such as HLA-B*07:02, correlate with immune-hot tumours in this subgroup. HLA-B*07:02, common in Europeans, presents proline-enriched neopeptides derived from AAS4 mutations. Supporting this, B*07:02-positive cancer cells harbouring AAS4-type mutations stimulated T-cell proliferation in vitro. These results show that neoantigen quality, not merely quantity, dictates antitumour immunity, explain inconsistent immunotherapy responses in MMR-deﬁcient cancers, and advocate incorporating amino acid substitution patterns into predictive biomarkers and therapy design.  \nKeywords Cancer; Mutational Signatures; Mutations; Immunotherapy; Antitumor Immunity  \nSubject Categories Cancer; Computational Biology  \n[https://doi.org/10.1038/s44320-026-00193-x](https://doi.org/10.1038/s44320-026-00193-x)  \nReceived 21 May 2025; Revised 19 December 2025; Accepted 13 January 2026  \nPublished online: 28 January 2026  \nIntroduction  \nMutational signatures refer to the speciﬁc patterns of mutations (also known as mutational footprints) that arise in cancer genomes due to various mutagenic processes (Kucab et al, 2019; Helleday  \net al, 2014; Australian Pancreatic Cancer Genome Initiative et al, 2013; Nik-Zainal et al, 2015; Alexandrov et al, 2020) . These processes might be driven by exposure to external agents like tobacco smoke (Alexandrov et al, 2016) or ultraviolet (UV) radiation (Hayward et al, 2017), internal factors like DNA repair deﬁciencies (Volkova et al, 2020; Zou et al, 2021) or the activities of speciﬁc enzymes (Alexandrov et al, 2020), and even certain biological processes such as aging (Alexandrov et al, 2020) . Understanding these signatures can help to elucidate the history of mutagenic exposures and the processes driving a particular cancer’s development. A deeper understanding of mutational signatures could also reveal therapeutic vulnerabilities of various tumours. For instance, identifying a signature linked to mismatch repair deﬁciency might suggest potential beneﬁt from immune  \ncheckpoint inhibitors (Boiarsky et al, 2024; Gulhan et al, 2024) .  \nThe analysis of mutational signatures has become a basic component in cancer genomics. While this growth in the ﬁeld is stunning, it is essential to consider potential constraints in its widening scope. Beyond a few pioneering studies focusing primarily on APOBEC3-related signatures (Boichard et al, 2019; Butler and Banday, 2023; DiMarco et al, 2022; Driscoll et al, 2020), the link between mutational signatures and cancer immunity has remained an unexplored area of research. Increased activity of APOBEC3 is a major source of mutations in multiple cancer types, like breast, bladder and non-small cell lung cancer (NSCLC) and ","cbCaipjNdQRtLF6c","https://ap.wps.com/l/cbCaipjNdQRtLF6c","pdf",2007299,21,"English","# Introduction\n## Mutational signatures and cancer genomics\n## Links between mutational signatures and cancer immunity","[{\"question\":\"What core hypothesis does the study evaluate about mutations and immune response?\",\"answer\":\"Certain mutation sources preferentially create amino acid substitutions that evade immune recognition, producing immune-cold tumours regardless of tissue or mutation load.\"},{\"question\":\"How were amino acid substitution signatures identified in the work?\",\"answer\":\"The study combined analysis of 9300 cancer exomes with mutagenesis experiments to relate mutagens and DNA repair defects to amino acid substitution signatures.\"},{\"question\":\"What is distinctive about AAS4 and its impact on antitumour immunity?\",\"answer\":\"AAS4, linked to alkylating agents and mismatch repair deficiency and enriched in kidney and liver cancers, is associated with poorly immunogenic neoepitopes and immune-desert microenvironments, leading to poor immunotherapy response.\"},{\"question\":\"Why can some mismatch-repair–deficient cancers still show immune activity?\",\"answer\":\"In the AAS4 subgroup, certain HLA class I variants such as HLA-B*07:02 correlate with immune-hot tumours, where proline-enriched neopeptides stimulate T-cell proliferation in vitro.\"}]","Five dominant amino acid substitution signatures shape tumour immunity | PDF",1790057309,53,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6bd79a86d8498a55161b68f04623b5fb.webp",983,1305,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97bca2f608e8998219f449f9a0aa36ac.webp",982,1304,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa1ef9ffe37a01d8f5c9a5d5a48a970d.webp",981,1303,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3401565aebdce9b16822482931607c86.webp",980,1301]